GH1 and hydrops fetalis: In addition, the absence of event-driven evidence for hormonal therapies (e.g., testosterone, GH, triiodothyronine, and ghrelin) in HF remains a critical area for investigation, given the preliminary promise that these treatments hold for improving outcomes.